← Russell 3000 cross-section

COR Cencora, Inc.

Trailing twelve months to 2026-06-30 · as filed 2026-08-05, not restated
Consumer Staples

Scale

Market cap
$61.5bn
Revenue TTM
$332.8bn
Net income TTM
$2.6bn
Free cash flow
$4.1bn
Composite score
53.9
Sector rank
#195

Valuation

P / E
23.4
EV / EBITDA
17.3
EV / sales
0.2
FCF yield
6.60%
Earnings yield vs 10-yr
-0.46pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
0.8%
EBITDA margin
1.2%
ROE
86.0%
ROIC
25.4%
Revenue growth
5.1%

Insider activity, last 90 days

Net open-market
$-2.42m
Buyers
2
Sellers
1

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

Executive Summary This executive summary provides highlights from the results of operations that follow: • Revenue increased by $4.1 billion, or 5.1%, and $11.4 billion, or 4.8%, from the prior year quarter and nine-month period, respectively, primarily due to growth in both reportable segments. Healthcare Solutions’ gross profit increased by $565.4 million, or 31.2%, and $1,365.1 million, or 26.5%, from the prior year quarter and nine-month period, respectively. The increase from the prior year quarter is primarily due to the February 2026 acquisition of OneOncology and increased pharmaceutical sales. …Cencora, Inc., 10-Q, period ended 2026-06-30, filed 2026-08-05

Read the full passage →